Outsourcing Pharma

MARCH 1, 2024

a prominent figure in metabolomics solutions, has launched a seminal integrated bioinformatics platform, aiming to redefine metabolomics analysis in life sciences research. Metabolon, Inc.,

Bioinformatics 73

Bioinformatics Life Science Research Clinical Development 73

BioTech 365

JULY 26, 2021

Kiromic Announces the Acquisition of InSilico Solutions Leveraging on Bioinformatics and Artificial Intelligence to Advance Clinical Development on Its Outpatient Allogeneic CAR-T for Solid Tumors Kiromic Announces the Acquisition of InSilico Solutions Leveraging on Bioinformatics and Artificial Intelligence to Advance … Continue reading → (..)

Bioinformatics 52

Bioinformatics Clinical Development Development 52

pharmaphorum

JULY 5, 2022

The new partnership will apply Mogrify’s cellular reprogramming and bioinformatics expertise to try to identify transcription factors – proteins which can turn specific genes on or off – that can be used to generate new cochlear hair cells. An estimated 1.57

In-Vivo 102

In-Vivo Bioinformatics Genetics Licensing 102

Drug Discovery World

SEPTEMBER 14, 2023

Enabling the discovery and development of novel mRNA-based cancer vaccines by leveraging Moderna’s knowledge of mRNA science and customised information from Immatics’ wealth of tumour and normal tissue data, which is included in XPRESIDENT, the company’s target discovery platform, and XCUBE, the company’s bioinformatics and AI platform.

Development 52

Development Vaccination Vaccine In-Vivo 52

Scienmag

JUNE 22, 2021

Credit: Insilco June 22, 2021, New York / Hong Kong — Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million from biotechnology experts to progress Insilico Medicine’s current therapeutic programs into (..)

Medicine 55

Medicine Clinical Trials Clinical Trials Clinical Development 55

The Pharma Data

MARCH 2, 2021

This new collaboration builds on the positive experience from previous partnerships with Gubra and combines Gubra’s proprietary streaMLine platform and expertise in obesity and peptide chemistry with Boehringer Ingelheim’s expertise in lead optimization and clinical development. Financial terms of the new agreement are not disclosed.

In-Vivo 52

In-Vivo Contract Manufacturing Bioinformatics Clinical Development 52

pharmaphorum

APRIL 15, 2021

In this way, we guide and inform clinical development plans, demonstrate how decisions are being made and define which decisions could have an impact on the final target indication of the therapy.”. We anticipate a revolution in digital solutions, such as artificial intelligence, bioinformatics and companion diagnostics.”.

Development 62

Development Manufacturing Production Bioinformatics 62